Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab + Chemo +/- SBRT for Oral/Oropharyngeal SCC
NCT06861712Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in oral squamous cell carcinoma (OSCC), oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Sun Yat-sen University. Planned start May 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
oral squamous cell carcinoma (OSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06861712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861712.